Neovacs S.A. (ALNEV) - Net Assets
Based on the latest financial reports, Neovacs S.A. (ALNEV) has net assets worth €18.03 Million EUR (≈ $21.08 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€22.14 Million ≈ $25.88 Million USD) and total liabilities (€4.10 Million ≈ $4.79 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Neovacs S.A. to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €18.03 Million |
| % of Total Assets | 81.47% |
| Annual Growth Rate | 13.09% |
| 5-Year Change | -58.92% |
| 10-Year Change | 1336.38% |
| Growth Volatility | 124.59 |
Neovacs S.A. - Net Assets Trend (2007–2025)
This chart illustrates how Neovacs S.A.'s net assets have evolved over time, based on quarterly financial data. Check how strategically is Neovacs S.A.'s equity deployed to assess the company's strategic physical and investment asset allocation.
Annual Net Assets for Neovacs S.A. (2007–2025)
The table below shows the annual net assets of Neovacs S.A. from 2007 to 2025. For live market cap and overall valuation, see ALNEV stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €18.03 Million ≈ $21.08 Million |
-0.15% |
| 2024-12-31 | €18.06 Million ≈ $21.12 Million |
-58.78% |
| 2023-12-31 | €43.82 Million ≈ $51.23 Million |
-0.93% |
| 2022-12-31 | €44.23 Million ≈ $51.71 Million |
+0.76% |
| 2021-12-31 | €43.90 Million ≈ $51.32 Million |
+299.80% |
| 2020-12-31 | €10.98 Million ≈ $12.84 Million |
+301.05% |
| 2019-12-31 | €2.74 Million ≈ $3.20 Million |
+12.36% |
| 2018-12-31 | €2.44 Million ≈ $2.85 Million |
+188.11% |
| 2017-12-31 | €845.75K ≈ $988.77K |
-32.64% |
| 2016-12-31 | €1.26 Million ≈ $1.47 Million |
-79.31% |
| 2015-12-31 | €6.07 Million ≈ $7.09 Million |
+9.00% |
| 2014-12-31 | €5.57 Million ≈ $6.51 Million |
+59.99% |
| 2013-12-31 | €3.48 Million ≈ $4.07 Million |
-3.88% |
| 2012-12-31 | €3.62 Million ≈ $4.23 Million |
-65.75% |
| 2011-12-31 | €10.57 Million ≈ $12.36 Million |
+27.73% |
| 2010-12-31 | €8.27 Million ≈ $9.67 Million |
+2446.72% |
| 2009-12-31 | €-352.58K ≈ $-412.20K |
-105.41% |
| 2008-12-31 | €6.51 Million ≈ $7.61 Million |
+230.56% |
| 2007-12-31 | €1.97 Million ≈ $2.30 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Neovacs S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4763911900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €187.25K | 1.04% |
| Other Comprehensive Income | €-25.27K | -0.14% |
| Other Components | €79.44 Million | 440.50% |
| Total Equity | €18.03 Million | 100.00% |
Neovacs S.A. Competitors by Market Cap
The table below lists competitors of Neovacs S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Reliance Global Group Inc
NASDAQ:RELIW
|
$34.10 |
|
Katapult Holdings Equity Warrants Exp 09 June 2026
NASDAQ:KPLTW
|
$37.58 |
|
Future Enterprises Limited
NSE:FEL
|
$38.23 |
|
Prairie Lithium Limited
AU:PL9
|
$40.17 |
|
US Solar Fund PLC
LSE:USFP
|
$32.65 |
|
Lion Financial Group Limited
NASDAQ:LGHLW
|
$29.69 |
|
Advent Technologies Holdings Inc
NASDAQ:ADNWW
|
$28.86 |
|
Reviva Pharmaceuticals Holdings Inc
NASDAQ:RVPHW
|
$28.10 |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Neovacs S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 18,062,164 to 18,034,429, a change of -27,735 (-0.2%).
- Net loss of 4,896,818 reduced equity.
- Other comprehensive income decreased equity by 807,744.
- Other factors increased equity by 5,676,827.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-4.90 Million | -27.15% |
| Other Comprehensive Income | €-807.74K | -4.48% |
| Other Changes | €5.68 Million | +31.48% |
| Total Change | €- | -0.15% |
Book Value vs Market Value Analysis
This analysis compares Neovacs S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.27x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | €-1612883.00 | €0.61 | x |
| 2010-12-31 | €6079522.00 | €0.61 | x |
| 2011-12-31 | €4767.07 | €0.61 | x |
| 2012-12-31 | €566.44 | €0.61 | x |
| 2013-12-31 | €190.29 | €0.61 | x |
| 2014-12-31 | €1047.81 | €0.61 | x |
| 2015-12-31 | €1839.95 | €0.61 | x |
| 2016-12-31 | €1255546.00 | €0.61 | x |
| 2017-12-31 | €845746.00 | €0.61 | x |
| 2018-12-31 | €2436704.00 | €0.61 | x |
| 2019-12-31 | €1368954.50 | €0.61 | x |
| 2020-12-31 | €1372532.88 | €0.61 | x |
| 2021-12-31 | €176301.97 | €0.61 | x |
| 2022-12-31 | €14.66 | €0.61 | x |
| 2023-12-31 | €1245990.08 | €0.61 | x |
| 2024-12-31 | €1062480.24 | €0.61 | x |
| 2025-12-31 | €0.48 | €0.61 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Neovacs S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -27.15%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -3026.84%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.23x
- Recent ROE (-27.15%) is above the historical average (-391.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2007 | -284.69% | -3748.10% | 0.03x | 2.40x | €-4.92 Million |
| 2008 | -87.71% | -8519.86% | 0.01x | 1.65x | €-5.16 Million |
| 2009 | 0.00% | -1861.36% | 0.08x | 0.00x | €-6.73 Million |
| 2010 | -147.76% | -52466.34% | 0.00x | 1.76x | €-9.59 Million |
| 2011 | -102.85% | -106.68% | 0.59x | 1.65x | €-8.90 Million |
| 2012 | -759.50% | -35750845.00% | 0.00x | 6.60x | €-7.24 Million |
| 2013 | -1778.43% | -22997.13% | 0.00x | 19.85x | €-6.91 Million |
| 2014 | -303.69% | -5297.32% | 0.02x | 3.66x | €-7.76 Million |
| 2015 | -77.17% | -3166.39% | 0.01x | 1.85x | €-5.29 Million |
| 2016 | -1109.67% | -90312.20% | 0.00x | 7.43x | €-14.06 Million |
| 2017 | -1754.48% | -115618.20% | 0.00x | 13.80x | €-14.92 Million |
| 2018 | -442.40% | -7434.48% | 0.02x | 2.97x | €-11.02 Million |
| 2019 | -275.69% | -7932.63% | 0.01x | 2.75x | €-7.82 Million |
| 2020 | -55.94% | -20624.03% | 0.00x | 1.23x | €-7.24 Million |
| 2021 | -26.96% | -52389.03% | 0.00x | 1.11x | €-16.23 Million |
| 2022 | -8.02% | -319109.98% | 0.00x | 1.11x | €-7.97 Million |
| 2023 | -19.95% | -1639.16% | 0.01x | 1.08x | €-13.13 Million |
| 2024 | -182.23% | -8984.51% | 0.02x | 1.22x | €-34.72 Million |
| 2025 | -27.15% | -3026.84% | 0.01x | 1.23x | €-6.70 Million |
Industry Comparison
This section compares Neovacs S.A.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $9,474,949
- Average return on equity (ROE) among peers: -46.57%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Neovacs S.A. (ALNEV) | €18.03 Million | -284.69% | 0.23x | $33.63 |
| Abionyx Pharma SA (ABNX) | $14.61 Million | -170.23% | 0.99x | $80.59 Million |
| Abivax SA (ABVX) | $34.65 Million | -45.66% | 0.56x | $8.28 Billion |
| Adocia (ADOC) | $28.04 Million | -66.34% | 1.21x | $93.64 Million |
| Aelis Farma SA (AELIS) | $2.38 Million | -114.51% | 1.64x | $16.89 Million |
| Biophytis S.A. (ALBPS) | $11.67 Million | -44.85% | 0.16x | $2.38 Million |
| Cellectis (ALCLS) | $6.40 Million | 0.00% | 0.20x | $242.68 Million |
| Advicenne (ALDVI) | $-19.07 Million | 0.00% | 0.00x | $29.81 Million |
| Genoway (ALGEN) | $14.56 Million | -2.22% | 1.23x | $31.09 Million |
| Integragen (ALINT) | $3.93 Million | -21.94% | 1.20x | $1.00 Million |
| Medesis Pharma SA (ALMDP) | $-2.42 Million | 0.00% | 0.00x | $1.80 Million |
About Neovacs S.A.
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for autoimmune diseases using its Kinoid technology. The company's product pipeline includes Kinoid, a therapeutic vaccine which allows the immune system to generate natural polyclonal antibodies. IF… Read more